RNA-Based Therapeutics for Selective Remodeling of Pathological Cardiac Tissue

Abstract

RNA-based therapeutics have rapidly emerged as a transformative approach in cardiology, offering novel strategies for the selective remodeling of pathological cardiac tissue. This review explores the scientific underpinnings, clinical evidence, and practical applications of RNA-targeted interventions in the management of cardiac fibrosis, hypertrophy, and heart failure. Emphasis is placed on the molecular mechanisms that enable selective targeting, the evolving clinical landscape shaped by recent trials, and the integration of these therapies into current management algorithms. We discuss the implications for patient care and future research directions, providing clinicians and healthcare professionals with a comprehensive overview of this advancing field.

Introduction

The burden of cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, with pathological cardiac remodeling playing a central role in disease progression. Traditional pharmacological interventions primarily focus on symptomatic relief and risk factor modification; however, they often fail to address the underlying molecular drivers of pathological remodeling. In recent years, RNA-based therapeutics have garnered significant interest due to their unique capacity to modulate gene expression and target pathogenic pathways at a fundamental level. This review offers an in-depth examination of the development, mechanisms, and clinical relevance of RNA-based therapies for selective remodeling of diseased cardiac tissue, aiming to inform practicing clinicians and researchers about the latest advances and future prospects.

Epidemiology / Disease Burden

Cardiac remodeling encompasses a spectrum of structural and functional changes in the myocardium, frequently resulting from ischemic injury, hypertension, or genetic predispositions. Globally, heart failure—often the culmination of adverse remodeling—affects over 64 million people, imposing significant healthcare costs and impacting quality of life. Fibrotic and hypertrophic changes underlie a majority of heart failure cases, and current therapies have limited efficacy in reversing established tissue changes. The persistent high prevalence and poor outcomes associated with maladaptive remodeling underscore the urgent need for innovative therapies that can selectively target diseased cardiac tissue while preserving healthy myocardium.

Pathophysiology

Pathological cardiac remodeling is characterized by altered cardiomyocyte function, fibroblast activation, extracellular matrix (ECM) deposition, and inflammatory signaling. The interplay of signaling pathways—including TGF-β, NF-κB, and microRNAs—drives maladaptive changes that culminate in fibrosis, myocyte apoptosis, and contractile dysfunction. Aberrant gene expression patterns are central to these processes, making RNA-based interventions particularly attractive. By targeting messenger RNAs (mRNAs) or non-coding RNAs implicated in fibrogenesis and hypertrophy, RNA-based therapeutics offer the potential for selective modulation of pathogenic pathways with molecular precision.

Risk Factors

Risk factors for pathological remodeling are multifactorial and include longstanding hypertension, myocardial infarction, valvular heart disease, diabetes, and genetic syndromes affecting structural proteins or regulatory RNAs. Environmental exposures, such as chronic alcohol consumption and certain chemotherapeutic agents, can also precipitate remodeling. The identification of these risk factors is critical for early intervention and for stratifying patients who may benefit most from targeted RNA-based therapeutics.

Clinical Features

Clinically, pathological cardiac remodeling manifests as progressive heart failure, arrhythmias, and reduced exercise tolerance. Symptoms range from asymptomatic ventricular dysfunction to overt congestion, fatigue, and syncope. Imaging modalities such as echocardiography and cardiac MRI reveal structural changes, including ventricular dilation, wall thinning, and increased myocardial stiffness. Biomarkers such as NT-proBNP and galectin-3 may indicate ongoing remodeling and fibrosis, aiding in early detection and monitoring of therapeutic response.

Diagnosis

The diagnosis of pathological remodeling relies on a combination of clinical assessment, imaging, and biomarker evaluation. Echocardiography remains the cornerstone for assessing chamber size, wall thickness, and ventricular function. Advanced imaging, including cardiac MRI with late gadolinium enhancement, provides detailed characterization of myocardial fibrosis. Genetic testing may be warranted in patients with familial cardiomyopathies or unexplained remodeling. Integration of multi-omics data, including transcriptomics and proteomics, is increasingly used in research settings to identify molecular signatures amenable to RNA-based intervention.

Treatment & Management

Current management of pathological cardiac remodeling involves neurohormonal blockade (ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid antagonists) and device-based therapies for advanced cases. These treatments slow disease progression but are largely non-selective and do not reverse established fibrosis or hypertrophy. RNA-based therapeutics, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and microRNA modulators, represent a new class of agents that can downregulate or restore expression of specific genes involved in remodeling. Early-phase clinical trials have demonstrated the feasibility of targeting key mediators such as TGF-β, CTGF, and profibrotic microRNAs, offering hope for more effective and personalized interventions.

Recent Advances / Emerging Therapies

Recent advances in RNA technology have enabled the development of highly selective and stable molecules capable of systemic delivery and targeted uptake by cardiac tissue. Lipid nanoparticle formulations and conjugated delivery systems have improved bioavailability and tissue specificity. Notably, agents targeting miR-21 and miR-29, both implicated in cardiac fibrosis, have shown promise in preclinical models by reversing ECM deposition and improving ventricular function. CRISPR-based RNA editing technologies are being explored for precise correction of pathogenic mutations, though these remain in the experimental stage. Ongoing clinical trials are evaluating the safety and efficacy of ASOs and siRNAs in patients with heart failure and hypertrophic cardiomyopathy, with early data indicating favorable biomarker and imaging outcomes.

Guideline Recommendations

Current clinical guidelines do not yet formally endorse RNA-based therapeutics for cardiac remodeling outside of research protocols. However, expert consensus statements from leading cardiovascular societies highlight the potential of RNA-targeted interventions for high-risk populations and urge enrollment in clinical trials. Guidelines emphasize the importance of comprehensive risk assessment, consideration of comorbidities, and the need for multidisciplinary care teams when evaluating candidates for emerging RNA-based therapies.

Conclusion

RNA-based therapeutics represent a paradigm shift in the management of pathological cardiac remodeling, offering the potential for selective, mechanism-based interventions that address the root causes of disease progression. As clinical evidence accumulates, these therapies may become integral to personalized medicine strategies for patients with high-risk or refractory cardiac pathology. Continued research, robust clinical trials, and integration into multidisciplinary care pathways will be essential for optimizing outcomes and translating scientific advances into routine clinical practice.